Prometic Life Sciences to present at two upcoming June investor conferences

May 30, 2019

LAVAL, QUEBEC, CANADA; ROCKVILLE, MD, USA and CAMBRIDGE, UK – May 30, 2019 – Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic), a biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, today announced that members of the management team will provide a business overview and update at the 2019 Jefferies Global Healthcare Conference at 14:30 EDT on Thursday, June 6, 2019 and at the Raymond James Life Sciences & MedTech Conference at 15:35 EDT on Wednesday, June 19, both in New York, NY.

The presentations will be webcast live on the Webcasts page of the Investors & Media section of Prometic's website, or by following the links below in your web browser. An archived replay of each webcast will be available on Prometic's website for at least 7 days after each live event concludes.

 

·     Jefferies: http://wsw.com/webcast/jeff118/pli/

·     Raymond James: http://wsw.com/webcast/rj115/pli/

 

About Prometic

Prometic (www.prometic.com) is an innovative biopharmaceutical corporation with a broad pipeline of small molecule therapeutics under development to treat unmet needs in patients with liver, respiratory and kidney disease, including rare diseases. Prometic's differentiated research involves the study of two G-protein-coupled-receptors, GPR40 and GPR84. These drug candidates have a dual mode-of-action as agonists ("stimulators") of GPR40 and antagonists ("inhibitors") of GPR84. Our lead drug candidate, PBI-4050, is expected to enter Phase 3 clinical studies for the treatment of Alström Syndrome in 2019. A second drug candidate, PBI-4547, is expected to enter Phase 1 clinical studies in 2019. Prometic also has leveraged its experience in bioseparation technologies to isolate and purify biopharmaceuticals from human plasma. The lead plasma-derived therapeutic product is Ryplazim™ (plasminogen) which the Company expects to file a BLA with the US FDA in 2019 seeking approval to treat patients with congenital plasminogen deficiency. The Corporation also operates a contract development and manufacturing operation in the United Kingdom, deriving revenue through sales of affinity chromatography media. Prometic has active business operations in Canada, the United States and the United Kingdom. For more information, please visit www.prometic.com.

 

Forward Looking Statements

This press release contains forward-looking statements about Prometic’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, Prometic’s ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Prometic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in Prometic’s Annual Information Form for the year ended December 31, 2018, under the heading "Risk and Uncertainties related to Prometic’s business". As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.

For further information please contact:

Bruce Pritchard

b.pritchard@prometic.com

450.781.0115

 

Patrick Sartore

p.sartore@prometic.com

450-781-0115

Previous Article
Prometic presents new data on PBI-4050 and its mechanism of action on kidney fibrosis at the 56th ERA/EDTA congress
Prometic presents new data on PBI-4050 and its mechanism of action on kidney fibrosis at the 56th ERA/EDTA congress

Prometic presents new data on PBI-4050 and its mechanism of action on kidney fibrosis at the 56th fibrosis ...

Next Article
Prometic presents new PBI-4050 and Ryplazim (plasminogen) data on lung fibrosis at the 2019 ATS conference
Prometic presents new PBI-4050 and Ryplazim (plasminogen) data on lung fibrosis at the 2019 ATS conference

Prometic today announced the presentation of three scientific posters on the Company’s lead small molecule ...